Needham analyst Gil Blum maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today and set a price target of $41.00. Discover outperforming stocks and invest smarter with Top ...
Non-Cartesian actuators are improving applications where they weren't even feasible before. Full definition of their dynamics and kinematics helps designers extract maximum performance from these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback